论文部分内容阅读
高原肺水肿(taro)是一种常见的。严重的、偶尔可致死的高原病。是使游访喜玛拉雅山的人们丧失能力的重要原因。本病主要累及年青人,特别是儿童和青少年。在平原体检健康的人,也不能保证不发生HAPO。居住高原者去平原停留一段时间后又重返高原常易患此病,乘飞机或汽车比步行登山的人容易患病。本病发病率约为0.1～15％。虽然通过缓慢登山和服用乙酰唑胺可以预防,但许多旅游者和随行医生还不清楚此病的严重性和致死的危害性。如早期认识其症状和体征并及时治疗能很快治愈。不要强迫缓慢登山适应的人保持集体休息,一且出现HAPO症状的患者,即应送往海拔较低地区。
High altitude pulmonary edema (taro) is a common. Serious, occasionally deadly plateau disease. Is an important reason for disabling people visiting the Himalayas. The disease mainly affects young people, especially children and adolescents. There is no guarantee that HAPO will not occur in people who are healthy in the plain. Living plateaus to the plains to stay for a period of time and then return to the plateau are often susceptible to the disease, by plane or car than walking mountain climbing susceptible to illness. The incidence of the disease is about 0.1 to 15%. Although slow climbing and taking acetazolamide can be prevented, many travelers and attending physicians are not yet aware of the seriousness and lethal nature of the disease. Early recognition of their symptoms and signs and timely treatment can be cured quickly. Do not force people with slow mountaineering to stay in groups, and those with HAPO symptoms should be sent to lower elevations.